Wolsong unit 1, the first PHWR (Pressurized Heavy Water Reactor) in Korea, was permanent shut down in 2019. In Korea, according to the Nuclear Safety Act, the FDP (Final Decommissioning Plan) must be submitted within 5 years of permanent shutdown. According to NSSC Notice, the types, volumes, and radioactivity of solid radioactive wastes should be included in FDP chapter 9, Radioactive Waste Management, Therefore, in this study, activation assessment and waste classification of the End shield, which is a major activation component, were conducted. MCNP and ORIGEN-S computer codes were used for the activation assessment of the End shield. Radioactive waste levels were classified according to the cooling period of 0 to 20 years in consideration of the actual start of decommissioning. The End shield consists of Lattice tube, Shielding ball, Sleeve insert, Calandria tube shielding sleeve, and Embedment Ring. Among the components composed for each fuel channel, the neutron flux was calculated for the components whose level was not predicted by preliminary activation assessment, by dividing them into three channel regions: central channel, inter channel, and outer channel. In the case of the shielding ball, the neutron flux was calculated in the area up to 10 cm close to the core and other parts to check the decrease in neutron flux with the distance from the core. The neutron flux calculations showed that the highest neutron flux was calculated at the Sleeve insert, the component closest to the fuel channel. It was found that the neutron flux decreased by about 1/10 to 1/20 as the distance from the core increased by 20 cm. The outer channel was found to have about 30% of the neutron flux of the center channel. It was found that no change in radioactive waste level due to decay occurred during the 0 to 20 years cooling period. In this study, activation assessment and waste classification of End Shield in Wolsong unit 1 was conducted. The results of this study can be used as a basis for the preparation of the FDP for the Wolsong unit 1.

프리지아 ‘Sunny Gold’는 농촌진흥청 국립원예특작과학원 에서 2010년 노랑색 반겹꽃 프리지아 육성계통 ‘036010’을 모본으로 진노란색 홑꽃 ‘Golden Flame’을 부본으로 교배하여 획득한 종자로부터 2011년 진노란색 겹꽃의 향기가 강한 프리지아 계통을 선발하여 품종화 하였다. 2011년부터 2016년까지 개화 생육특성검을 수행하였으며 핵심수요자의 기호도 평가를 통해 선발되어 2017년 ‘Sunny Gold’ 로 명명되었다. ‘Sunny Gold’는 RHS color chart YO17B의 노란색 겹꽃 프리지아 품종으로 화폭은 6.7cm로 대조품종 ‘Golden Flame’ 6.1cm에 비해 크고, 분지수는 6.5로 다수확성 품종이다. 초장이 101.9cm로 초세가 강하다. ‘Sunny Gold’의 소화수 및 소화장은 각각 13.0개, 9.3cm이며 개화소요일수는 137.7일이다. 이 품종의 절화수명은 약 9일이며 자구번식력은 5.3배로 대조 품종 ‘Golden Flame’ 4.3배에 비해 우수하다. 전자코를 이용한 PCA분석결과 PC1과 PC2는 각각 99.3%와 0.6%로 전체 변이량의 99.9%를 반영하고 있다. Rader plot 분석결과 총 6개 센서에서 모두 ‘Sunny Gold’의 센서값이 향기가 강한 상용품종 ‘Yvonne’의 값에 비해 높게 나타나 ‘Sunny Gold’의 향기가 더 강한 것으로 나타났다.

Radioisotope ADME (RI-ADME) studies are enabling visualization of the biodistribution in molecular imaging. We applied RI-ADME to investigate the tumor targeting capacity and biodistribution of trastuzumab-monomethyl auristatin F (LCB14-0110) in JIMT-1 xenograft mice and healthy marmoset. The LCB14-0110 was labelled with 125I. 125I-LCB14-0110 was intravenously administered to the animals. The gamma-count and single-photon emission computed tomography/computed tomography (SPECT/CT) was conducted for biodistributioon and bioimaging of the biopharmaceutics. Tumor uptake in xenograft mice was highest at three-day after 125I-LCB14-0110 administration in both the biodistribution and SPECT/CT bioimaging. Alternatively, blood and organ tissues showed gradual decrease in radioactivity over time. In marmosets, radioactivity in all organ tissues rapidly reduced and no specific targeting of organs was observed in the biodistribution study and SPECT/CT imaging. Hence, 125ILCB14- 0110 demonstrated effective tumor targeting capacity and accumulated in JIMT-1 cell-bearing mice. However, accumulation did not occur in the organs of xenograft mice. Additionally, marmosets showed rapidly decrease in radioactivity throughout the entire body without accumulation in the normal organs. We also confirmed that the drug distribution was similar in normal organs between the two experimental animal species except spleen. Therefore, 125I is expected to be a useful tool in the study of RI-ADME in biopharmaceuticals through minimal antibody modification.

Cryopreservation of bovine embryos is used to efficiently implant surrogate mothers. It has been widely accepted that high lipid content in the oocyte interrupts its survival during freeze-thaw cycles. Serum component in the culture medium is thought to increase the embryo`s lipid contents. Conversely, L-carnitine stimulates lipid metabolism by transporting long chain fatty acids into the mitochondria. Objective of this study was to analyze the effect of L-carnitine supplementation in IVM medium and defined IVC medium on the development, lipid contents and the cryosurvival of bovine IVF embryos. 0.0, 1.5, 3.0 and 6.0 mM L-carnitine was supplemented in IVM medium, respectively (IVM-LC 0.0, LC 1.5, LC 3.0 and LC 6.0). Development rate from the 2cell to the morula stages was higher in IVM-LC 3.0 groups than those of IVM-LC 6.0 (p<0.05). But there were no significant differences among the other groups in the blastocyst rates and lipid content results. When 0.0, 1.5, 3.0 and 6.0 mM L-carnitine were supplemented in IVC medium (IVC-LC 0.0, LC 1.5, LC 3.0 and LC 6.0), development competence was not significantly different between those embryos. Lipid contents of embryos treated L-carnitine (IVC-LC 1.5, 3.0 and 6.0) were significantly lower than embryos of non-treated group. L-carnitine was supplemented 0.0, 1.5, 3.0, 6.0 mM during IVM and 3.0 mM during IVC (LC 0.0 - 3.0, LC 1.5 – 3.0, LC 3.0 – 3.0, LC 6.0 – 3.0) and cryosurvival of blastocysts confirmed after freezing-thawing. There were no significant differences on development, but LC 3.0 – 3.0 was significantly lower lipid contents than other groups. And LC 3.0 – 3.0 had better survival rates and hatched rates of blastocysts than LC 0.0 – 0.0. In conclusion, supplementation of L-carnitine in defined IVC medium decreases lipid contents. And L-carnitine supplementation improves cryosurvival and developmental ability of bovine IVF embryos.

The early-onset familial Alzheimer's disease (EOFAD/ FAD), the less common type of Alzheimer's disease (AD) currently affects a vast number of individuals worldwide. This type is being inherited as an autosomal dominant fashion. Missense mutations on Amyloid precursor protein (APP) and Presenilins 1 and 2 (PSEN1 & PSEN2) are known as major genetic factors in FAD. Conversely, missense mutations on microtubule-associated protein tau (MAPT) are also thought to involve. Up to date, several triple-transgenic animal models with muted forms of the human APP, PSENs and MAPT have been reported. Compared to other animals, canines are more emotional and their disease signs can be easily diagnosed. This attempt was to develop a triple transgenic canine model for the AD. We have obtained the coding sequences of APP, PSEN1 and MAPT from Dana-Farber/Harvard Cancer Center DNA resource core at HMS and incorporated several common AD mutations. The transgenic construct is composed of hNSE (ENO2) promoter-driven three AD genes fused together with modified 2A sequences. It was transfected into the canine fetal fibroblasts which were then used to perform somatic cell nuclear transfer (SCNT). The viable transgenic embryos were obtained after in vitro culture and the GFP was detected. In this study, we have successfully produced viable triple transgenic canine cloned embryos using SCNT technique. These transgenic canine embryos will be further developed into canines with FAD. The transgenic canines will be a good candidate in the AD research field.

The aim of this study was to examine the effect of acteoside (the cyclin-dependent kinase inhibitor) on the SCNT efficiency with adult fibroblasts in dog. Canine adult fibroblasts were obtained from muscle and cell cycle of fibroblasts was synchronized by culturing to confluency, serum starvation and treating with 30 μM acteoside for 48 h. Cell cycle stages, cell cytotoxicity (apoptosis) and, prduction of reactive oxygen species (ROS) were analyzed using flow cytometry. The canine cells, prepared by confluent-cell culture or treating with 30 μM acteoside for 48 h, were injected into enucleated in vivo matured oocytes, the couplets were electrical fused and activated by calcium ionomycin. SCNT embryos using acteoside-treated fibroblasts were surgically transferred into oviducts of estrus cycle synchronized recipient dogs. In cell cycle synchronization (G0/G1), there was no significant difference between serum starvations (83.9%) and acteoside treated groups (81.3%) that were higher than confluent group (78.5%). In production of apoptosis, confluent and acteoside treated groups (4.3 and 4.5%, respectively) were generated less than serum starvation group (21.8%). In case of ROS, serum starvation group was induced a significantly higher than other groups. After synchronization of the donor cell cycle, either confluent or acteoside treated, cells were placed with enucleated in vivo-matured dog oocytes, fused by electric stimulation, activated, and transferred into naturally estrus-synchronized surrogates. Fusion and cleavage rate of acteoside treated group were 64.1 and 41.5%, which were higher than those of confluent group (53.9 and 20.6%, respectively). The reconstructed embryo development rates to 4-cell and 8-cell in acteoside treated group were 29.5 and 14.8%, respectively, while confluent group showed 11.1 and 3.2%, respectively. Total 54 SCNT embryos using acteoside-treated fibroblasts were transferred into oviducts of 2 recipient dogs and one recipient finally delivered one puppy, whereas din`t detected pregnancy on transfer of cloned embryos reconstructed with confluent cells in 6 surrogate dogs. In conclusion, the results of the current study demonstrated that canine fibroblasts could be successfully arrested at the G0/G1 stage with reduced the formation of ROS and apoptosis after acteoside treatment. This results may contribute to improve the effi-ciency of canine SCNT. * This research was supported by iPET (Grants 110056-3), Ministry for Food, Agriculture, Forestry and Fisheries, Republic of Korea.

Acteoside acts as an anti-oxidative activity and anti-apoptosis in the cells. But, it has been not studied on maturation and development of porcine oocytes. The aims of the present study were to examine the effects of acteoside on the morphological progress of meiosis, developmental competence, and ROS in porcine oocytes. Oocytes were matured in tissue culture medium-199, supplemented with acteoside at various concentrations: 0 (control), 10, 30 and 50 μM. The oocytes maturation rates of groups supplemented with acteoside were no significantly different (81.13, 85.96, 82.95 and 83.68%, respectively). Level of ROS was significantly decreased in acteoside treated group. Furthermore, the parthenogenetic blastocyst rate was significantly improved in 10 μM acteoside treated group compared with control group (44.83 vs. 27.75%). And we investigated effect of acteoside on the oocytes condition represented by cytoplasmic maturation by homogeneous distribution and formation of cytoplasmic organelles and regulation of apoptosis-related genes. In the results. during IVM, 10 μM acteoside treated oocytes showed that the mitochondria and lipid droplet were smaller and homogeneous distribution in cytoplasm compare with control oocytes. And reverse transcription polymerase chain reaction (RTPCR) of parthenogenetic blstocysts revealed that acteoside increased the anti-apoptotic genes (Mcl-1, Bcl-2 and Bcl-xL), whereas reduced the expression of pro-apoptotic genes (Bax and Bak). In conclusion, based on the results, the effect of acteoside on IVM was not attractive. However, in acteoside treated group, cytoplasmic maturation seemed to be improved with morphologically uniform distribution of cytoplasmic organelles. Furthermore, embryonic development in acteoside treated group was significantly highly increased than that of non-treated group. Our results represents that addition of acteoside to the IVM medium has a beneficial effect in physiology of porcine oocytes, providing a improved method for porcine oocytes in vitro. * This work was supported by a grant (Code# PJ008148) from BioGreen21 Program, Rural Development Administration, Republic of Korea.